McKesson (NYSE:MCK) Releases Earnings Results, Beats Estimates By $0.15 EPS

McKesson (NYSE:MCK) announced its quarterly earnings data on Wednesday. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15, FiscalAI reports. The firm had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 303.62% and a net margin of 1.09%.The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $8.03 earnings per share. McKesson updated its FY 2026 guidance to 38.800-39.200 EPS.

Here are the key takeaways from McKesson’s conference call:

• Raised FY26 guidance to $38.80–$39.20 in adjusted EPS (17%–19% growth) and tightened revenue guidance to 12%–16%, signaling management’s confidence in sustained momentum.
• Reported strong third-quarter results with revenue of $106.2B (up 11%), adjusted diluted EPS of $9.34 (up 16%), robust free cash flow (TTM $9.6B), and $680M of share repurchases in the quarter.
• Oncology, multispecialty, and biopharma services drove outsized growth — oncology revenues +37% and operating profit +57% — with Prism Vision and Core Ventures adding meaningfully and expected to be accretive to FY26 segment profit.
• GLP-1 distribution was $14B (up 26% YoY) and specialty distribution remains a growth driver for North American pharma, but management warned quarter-to-quarter variability and is monitoring IRA/Part D and other policy dynamics.
• Progress on portfolio actions: transition service agreements are in place for the medical‑surgical separation with an IPO targeted in H2 2027 (market‑dependent), and the Norway divestiture is complete — actions aimed at unlocking shareholder value.

McKesson Stock Performance

Shares of McKesson stock traded down $12.65 on Friday, hitting $945.15. The company’s stock had a trading volume of 218,649 shares, compared to its average volume of 688,331. The company has a market capitalization of $116.66 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 1.35 and a beta of 0.40. McKesson has a 1 year low of $583.55 and a 1 year high of $971.93. The firm has a fifty day moving average price of $827.03 and a 200-day moving average price of $777.93.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Wall Street Analysts Forecast Growth

Several analysts have commented on MCK shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Wells Fargo & Company boosted their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday. Robert W. Baird set a $968.00 price target on shares of McKesson in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “buy (a-)” rating on shares of McKesson in a research report on Monday, December 29th. Finally, Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $918.93.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 beat and raised guidance — McKesson reported Q3 EPS above consensus and revenue growth of ~11.4% year-over-year, then raised full‑year adjusted EPS guidance to $38.80–$39.20, which lifted investor confidence. BusinessWire: Q3 Results & Guidance
• Positive Sentiment: Market reaction: shares surged and hit record highs — Wall Street cheered the results and outlook, sending MCK to an all‑time intraday high and a >15% move on the day as traders re‑rated growth expectations. TipRanks: Stock Surges 16% Investing.com: All‑time High
• Positive Sentiment: Specialty/oncology and tech businesses powering outlook — Management cited accelerating oncology and biopharma services and strength in specialty/technology offerings as the drivers behind the raised profit forecast. Reuters: Profit Forecast Raised
• Neutral Sentiment: Analyst price target moves mixed — Wells Fargo bumped its target to $925 but kept an “equal weight” view; Mizuho lifted its target to $885 with a neutral rating. These changes signal analyst support but leave upside limited relative to current levels. AmericanBankingNews: Wells Fargo PT Benzinga: Mizuho PT
• Negative Sentiment: Operating cash flow weakness and higher liabilities — Some reports highlight materially weaker operating cash flow this quarter and an increase in total liabilities, which could pressure free cash flow and leverage metrics. QuiverQuant: Cash Flow Concerns
• Negative Sentiment: Insider and institutional selling noted — Recent disclosures show insider sales and some large institutional position reductions, which investors may view as a cautionary signal even amid the upbeat quarter. QuiverQuant: Insider/Institutional Activity

Insider Transactions at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.08% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MCK. State of Wyoming acquired a new stake in McKesson in the 2nd quarter valued at $29,000. Turning Point Benefit Group Inc. acquired a new position in McKesson during the third quarter worth $117,000. Osterweis Capital Management Inc. purchased a new position in McKesson during the second quarter valued at $166,000. Triumph Capital Management acquired a new stake in shares of McKesson in the third quarter valued at about $179,000. Finally, Wealth Watch Advisors INC acquired a new stake in shares of McKesson in the third quarter valued at about $180,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.